Abstract
The selective 5-hydroxytryptamine2-(5-HT2)-receptor-blocking agent ketanserin was given in a dose of 10 mg intravenously to nine patients with Raynaud's phenomenon. The effect on blood flow was assessed by photopletysmography and measurments of skin temperature. Digital blood flow and skin temperature increased significantly after ketanserin injection, whereas the placebo (saline 9 g/l) had no such effect. This study suggests that ketanserin may be useful in the treatment of Raynaud's phenomenon.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blunt R. J., Porter J. M. Raynaud syndrome. Semin Arthritis Rheum. 1981 May;10(4):282–308. doi: 10.1016/0049-0172(81)90006-8. [DOI] [PubMed] [Google Scholar]
- Coffman J. D., Davies W. T. Vasospastic diseases: a review. Prog Cardiovasc Dis. 1975 Sep-Oct;18(2):123–146. doi: 10.1016/0033-0620(75)90002-x. [DOI] [PubMed] [Google Scholar]
- HALPERN A., KUHN P. H., SHAFTEL H. E., SAMUELS S. S., SHAFTEL N., SELMAN D., BRICH H. G. Raynaud's disease, Raynaud's phenomenon, and serotonin. Angiology. 1960 Jun;11:151–167. doi: 10.1177/000331976001100301. [DOI] [PubMed] [Google Scholar]
- Halperin J. L., Coffman J. D. Pathophysiology of Raynaud's disease. Arch Intern Med. 1979 Jan;139(1):89–92. [PubMed] [Google Scholar]
- Van Nueten J. M., Janssen P. A., De Ridder A., Vanhoutte P. M. Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 468). Eur J Pharmacol. 1982 Feb 5;77(4):281–287. doi: 10.1016/0014-2999(82)90130-3. [DOI] [PubMed] [Google Scholar]
- Wenting G. J., Man in 't Veld A. J., Woittiez A. J., Boomsma F., Schalekamp M. A. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br Med J (Clin Res Ed) 1982 Feb 20;284(6315):537–539. doi: 10.1136/bmj.284.6315.537. [DOI] [PMC free article] [PubMed] [Google Scholar]